You can call MIRG.org toll-free at (1-888-802-6376)

Mesothelioma Articles

Phase I Study of SS1(dsFv)-PE38 Immunotoxin in Patients With Advanced Mesothelin-Expressing Malignancies

Date First Published: 2003-07-26

Date Last Modified: 2003-07-28

BASIC STUDY INFORMATION

PATIENT ABSTRACT:

Rationale:
Immunotoxins can locate tumor cells and kill them without harming normal cells. Immunotoxin therapy may be effective in treating advanced solid tumors.

Purpose:
Phase I trial to study the effect on the body of immunotoxin therapy in treating patients who have recurrent, unresectable advanced solid tumors.

Eligibility:
 •At least 18 years old
 •Measurable or evaluable disease
 •No CNS involvement
 •At least 4 weeks since anticancer therapy

Treatment Intervention:
Patients will receive an infusion of immunotoxin on days 1, 3, and 5. Treatment may be repeated every 4 weeks for up to three courses. Patients will be evaluated every 3 months.

Disclaimer:
This abstract is intended to give a brief overview of this clinical trial. To help determine whether the trial is appropriate for an individual, selected major eligibility criteria are listed above. To obtain more details related to trial eligibility and the treatment plan, please see the Health Professional abstract of this clinical trial. Information about ongoing clinical trials is available from the NCI Cancer.gov Web site.

STUDY LEAD ORGANIZATIONS:
 Center for Cancer Research
 David Kohler, PharmD, Protocol chair
 Ph: 301-496-4363

STUDY SITES AND CONTACTS

U.S.A.

Maryland

Bethesda

 Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support
 Patient Recruitment
 Ph: 888-NCI-1937

Source: Cancer.gov

Click here to return to current clinical trials page

***Please note that the clinical trials listed on this page have additional specific requirements. Call contacts listed for each trial for more detailed information.